KLK3 and prostate carcinoma: One study found that patients with PSA <4.0 ng/mL showed significantly worse prostate cancer-specific mortality (PCSM) than those with PSA of 4.0-10.0 ng/mL, particularly in patients with GS 9-10 prostate cancer [4].